GlassScriptPhysician profile
Richard T Leschek
NPI 1164429429
$18,995.48
in general payments reported to CMS, 2019-2025
80 companies · $2,510 in 2025
The $2,510 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,835 · 2020: $2,390 · 2021: $2,100 · 2022: $2,639 · 2023: $2,895 · 2024: $2,627 · 2025: $2,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,771 · Consulting Fee: $150 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,770.70 |
| Consulting Fee | $150.00 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,327.30 | 2019-2025 | |
| Abbvie INC. | $1,061.15 | 2019-2025 | |
| Biogen, INC. | $1,057.06 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Teva Pharmaceuticals USA, INC. | $1,006.67 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $943.99 | 2019-2025 | Qelbree |
| Lilly USA, LLC | $766.75 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Amgen INC. | $739.86 | 2019-2024 | Aimovig |
| Lundbeck LLC | $631.22 | 2019-2025 | Vyepti, Rexulti |
| Ucb, INC. | $614.63 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Emd Serono, INC. | $607.15 | 2019-2025 | Mavenclad |
| Genzyme Corporation | $544.21 | 2019-2025 | |
| Allergan, INC. | $498.77 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $475.69 | 2019-2025 | Amvuttra |
| Neurelis, INC. | $404.02 | 2020-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $377.84 | 2019-2025 | Nuplazid |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $373.68 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $365.88 | 2019-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $334.11 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $330.33 | 2019-2023 | Ultomiris |
| Tanabe Pharma America, INC. | $324.44 | 2019-2025 | Radicava |
| Sunovion Pharmaceuticals INC. | $289.39 | 2019-2022 | |
| Celgene Corporation | $288.36 | 2020-2025 | Zeposia |
| Eisai INC. | $284.26 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $272.73 | 2020-2025 | Acthar |
| Kyowa Kirin, INC. | $248.47 | 2020-2024 | Nourianz |
| Acorda Therapeutics, INC | $243.40 | 2019-2024 | Inbrija, Ampyra |
| Amneal Pharmaceuticals LLC | $240.03 | 2019-2025 | Rytary, Crexont, Ongentys |
| Jazz Pharmaceuticals INC. | $213.54 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $203.64 | 2019-2022 | |
| Grifols USA, LLC | $180.23 | 2019-2024 | Gamunex-C |
| Argenx US, INC. | $176.88 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Avanir Pharmaceuticals, INC. | $172.99 | 2019-2022 | |
| Csl Behring | $169.79 | 2019-2025 | Hizentra |
| Axsome Therapeutics, INC. | $165.95 | 2023-2025 | Sunosi, Symbravo |
| Mdd US Operations, LLC | $163.97 | 2020-2024 | Gocovri, Gocovri |
| Currax Pharmaceuticals LLC | $155.83 | 2022-2025 | Onzetra Xsail, Contrave |
| Adamas Pharmaceuticals, INC. | $142.74 | 2019-2020 | |
| Akcea Therapeutics, INC. | $127.44 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $122.88 | 2024-2025 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $122.79 | 2023-2025 | Nuedexta, Rexulti |
| Banner Life Sciences, LLC | $122.08 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $108.09 | 2023-2025 | Ztlido |
| Ani Pharmaceuticals, INC. | $105.61 | 2022-2023 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $96.47 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $92.75 | 2022-2023 | Trudhesa |
| Amylyx Pharmaceuticals, INC. | $91.57 | 2023-2024 | Relyvrio |
| Merck Sharp & Dohme LLC | $91.06 | 2021-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $90.08 | 2024-2025 | Wainua |
| Horizon Therapeutics Plc | $89.31 | 2022-2023 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $88.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $85.98 | 2021 | |
| Collegium Pharmaceutical, INC. | $77.14 | 2022 | |
| Arbor Pharmaceuticals, INC. | $75.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $71.89 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $67.17 | 2023 | Xeomin |
| Livanova USA, INC. | $66.74 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $64.39 | 2019 | |
| Assertio Therapeutics, INC. | $63.61 | 2019-2020 | |
| Avion Pharmaceuticals | $63.38 | 2022-2023 | Dhivy |
| Sk Life Science, INC. | $57.62 | 2021-2023 | |
| Promius Pharma LLC | $56.63 | 2019 | |
| Greenwich Biosciences, INC. | $54.85 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $46.87 | 2019-2020 | |
| Ge Healthcare | $45.12 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $40.25 | 2023 | Quviviq |
| Corium, LLC | $40.03 | 2023 | Adlarity |
| Azurity Pharmaceuticals, INC. | $37.30 | 2023 | Horizant |
| Medtronic, INC. | $26.20 | 2023 | Vanta Adaptivestim |
| Almatica Pharma LLC | $25.99 | 2021-2023 | Gralise |
| Insightec,INC | $22.98 | 2025 | Exablate |
| Nevro Corp. | $19.55 | 2024 | Senza |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.70 | 2021 | |
| Cycle Pharmaceuticals INC | $17.64 | 2025 | Bafiertam, Tascenso Odt |
| Avadel Cns Pharmaceuticals, LLC | $16.53 | 2024 | Lumryz |
| Invivyd INC | $16.09 | 2024 | Pemgarda |
| Life Molecular Imaging LTD | $15.08 | 2021 | |
| Sumitomo Pharma America, INC. | $14.26 | 2023 | Aptiom |
| Medtronic USA, INC. | $12.23 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Leschek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.